Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Desmopressin (DDAVP) Peptide
Synthetic vasopressin analog for diabetes insipidus and nocturnal enuresis.
What is Desmopressin (DDAVP)?
Desmopressin (DDAVP) is a vasopressin analog · hormonal peptide studied for central diabetes insipidus and primary nocturnal enuresis. Below is an educational overview of Desmopressin (DDAVP) peptide benefits, mechanism, common research protocols, dosage references, and known side effects.
Plain-Language Label Highlights
Brand names: DDAVP, Nocdurna, Stimate
Central diabetes insipidus, primary nocturnal enuresis, nocturia, mild hemophilia A and von Willebrand disease.
A synthetic version of antidiuretic hormone (ADH) that helps the kidneys hold on to water and helps blood clot.
Risk of severe, life-threatening hyponatremia (low blood sodium) — restrict fluids and monitor sodium.
- •Headache
- •Nausea
- •Nasal congestion (nasal form)
- •Facial flushing
- •Hyponatremia and seizures
- •Fluid overload
- •Thrombosis (rare, high doses)
- •Moderate-to-severe kidney impairment
- •History of hyponatremia
- •Polydipsia
- •Heart failure / fluid overload risk
Educational summary of the FDA prescribing information. Not a substitute for the full label or medical advice. Always discuss with a licensed prescriber.
Desmopressin (DDAVP) Mechanism of Action
Synthetic analog of arginine vasopressin with enhanced antidiuretic activity and negligible vasopressor effect. Acts on renal V2 receptors to increase water reabsorption; also increases factor VIII and vWF release.
Desmopressin (DDAVP) Research Areas & Benefits
Desmopressin (DDAVP) Dosage & Common Research Protocols
Intranasal 10–40 mcg/day or oral 0.1–0.8 mg/day.
Oral 0.2 mg at bedtime.
Protocols summarized for educational reference from published research. Not dosing guidance.
Desmopressin (DDAVP) Studies & Cited Research
Desmopressin for nocturnal enuresis
Effective short-term reduction of bedwetting in children.
Why we trust this source: Published in a peer-reviewed scientific journal with editorial and reviewer oversight.
Citations are linked to PubMed, Google Scholar, and Crossref searches so you can verify the source independently. All references are reviewed during our editorial passes (last reviewed June 1, 2026).
Desmopressin (DDAVP) Side Effects & Safety Considerations
- •FDA-approved.
- •Risk of hyponatremia — limit fluids around dosing.
Explore more peptides
Educational Information Only — Not Medical Advice
All content on this page is for educational and informational purposes only. It is not medical advice, diagnosis, or treatment. We make no claims that any peptide can diagnose, treat, cure, or prevent any disease. Peptides discussed are not FDA-approved for the indications listed unless explicitly stated otherwise.
Always consult a licensed healthcare provider before beginning any wellness protocol. Statements have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability, eligibility, and pricing may vary.
Ask the Library
Ask anything about peptides — answers come from our curated reference library with citations.